61 / 220
Conflict of interest statement
None declared.
Acknowledgements
This study was supported by a grant
(2015R1A2A1A15054540) from Basic Science Research
Program through the National Research Foundation of
Korea (NRF), Ministry of Science, ICT, and Future
Planning and a grant (no. HI14C23050000) from the
Korean Health Technology R&D Project, Ministry of
Health & Welfare, Seoul, Republic of Korea (J.L. Roh).
Appendix A. Supplementary data
Supplementary data related to this article can be found
at
http://dx.doi.org/10.1016/j.ejca.2016.05.002.
References
[1] A snapshot of head and neck cancer. Incidence and mortality.
http://www.cancer.gov/researchandfunding/snapshots/ headandneck[accessed 16.02.01].
[2]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin 2015; 65(2):87 e 108.
[3] SEER stat fact sheets: oral cavity and pharynx cancer.
http://seer. cancer.gov/statfacts/html/oralcav.html[accessed 16.02.01].
[4] SEER stat fact sheets: larynx cancer.
http://seer.cancer.gov/ statfacts/html/laryn.html[accessed 16.02.01].
[5]
Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;37(9625):1695 e 709.
[6]
Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005;16(Suppl. 6):vi7 e 12.
[7]
de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000;110(3 Pt 1):397 e 401.
[8]
Brouwer J, de Bree R, Hoekstra OS, Golding RP, Langendijk JA, Castelijns JA, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography suffi- cient? The Laryngoscope 2005;115(10):1813 e 7 .[9]
Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41(8):1369 e 79.
[10]
Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluo- rodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multi- center prospective study. J Clin Oncol 2010;28(7):1190 e 5.
[11]
Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med 2008;49(10): 1593 e 600.
[12]
Pohar S, Brown R, Newman N, Koniarczyk M, Hsu J, Feiglin D. What does PET imaging add to conventional staging of head and neck cancer patients? Int J Rad Oncol Biol Phys 2007;68(2): 383 e 7.
[13]
VanderWalde NA, Salloum RG, Liu TL, Hornbrook MC, O’Keeffe Rosetti MC, Ritzwoller DP, et al. Positron emission tomography and stage migration in head and neck cancer. JAMA Otolaryngol Head Neck Surg 2014;140(7):654 e 61.
[14]
Rohde M, Dyrvig AK, Johansen J, Sorensen JA, Gerke O, Nielsen AL, et al. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer Oxf Eng 1990 2014;50(13):2271 e 9.
[15]
Kim SY, Roh JL, Yeo NK, Kim JS, Lee JH, Choi SH, et al. Combined 18F-fluorodeoxyglucose-positron emission tomogra- phy and computed tomography as a primary screening method for detecting secondprimary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007;18(10): 1698 e 703.
[16]
Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100(10): 712 e 20.
[17] NCCN Clinical Practice Guidelines in Oncology. Head and neck
cancer. Version 2. 2014.
http://www.nccn.org/professionals/ physician gls/f_guidelines.asp#head-and-neck[accessed 16.02.01].
Fig. 3. Overall survival (OS) of the 122 patients with conventional work-ups (CWU)-determined stage I
e
II. (A) The patients with CWU
stage I and II disease did not differ in OS (
P
Z
0.317). (B) However, PET/CT re-staging stratified this population into groups with stage
I
e
IV disease. The OS declined significantly as the PET/CT stage increased (
P
Z
0.002).
I.S. Ryu et al. / European Journal of Cancer 63 (2016) 88
e
96
41